A 12 months after the distinguished medical journal JAMA was embroiled in controversy over a podcast seen as racist by critics, the American Medical Affiliation has appointed a outstanding health-equity researcher because the publication’s new editor-in-chief — the primary girl of coloration to carry the place.
Kirsten Bibbins-Domingo, a Black internist, epidemiologist, and health-equity researcher from the College of California, San Francisco, who has been a number one voice for equitable well being care throughout the Covid-19 pandemic, will lead the Journal of the American Medical Affiliation and the JAMA community of journals, the AMA introduced Monday.
Bibbins-Domingo is changing Howard Bauchner, a Boston pediatrician who held the place for 10 years, till he stepped down in June 2021 after JAMA aired a podcast and posted a tweet questioning whether or not structural racism exists in drugs. That incident led to an outcry over what many noticed as deeply embedded structural racism inside the journals and for having editors and editorial boards that have been overwhelmingly white.
commercial
Bibbins-Domingo, a professor of drugs and chair of the Division of Epidemiology and Biostatistics at the us Faculty of Medication, co-founded the us Middle for Weak Populations at Zuckerberg San Francisco Basic Hospital. Just lately named to the inaugural STATUS listing, STAT’s compilation of probably the most influential leaders within the life sciences, Bibbins-Domingo has spent her profession centered on erasing well being disparities, significantly in cardiovascular care.
She is going to begin her new place on July 1, taking up for Phil Fontanarosa, who has served as interim editor-in-chief since Bauchner’s departure. A white girl, Johns Hopkins College pediatrician Catherine D. DeAngelis, ran the journals from 2000-2011.
commercial
“That is a unprecedented time for science, drugs and public well being — one the place the chances for accelerating developments in human well being appear limitless, whereas deep challenges to reaching optimum well being for all appear intractable,” Bibbins-Domingo mentioned in a press release launched by JAMA. “Towards this backdrop, a trusted voice for science, drugs, and public well being has by no means been extra essential. … I couldn’t be extra excited to affix as editor-in-chief.”
The transfer was met with quick applause on Twitter. “Bravo and might’t wait on your management on this function,” mentioned Utibe R. Essien, an assistant professor of drugs on the College of Pittsburgh. “That is big information and an ideal selection,” tweeted Jeremy Faust, an ER doctor and editor-in-chief of MedPage As we speak.
The transfer was lauded by a few of JAMA’s fiercest critics. “Actually excited to see this,” tweeted Stella Safo, an HIV doctor in New York who helped begin a petition drive towards JAMA final 12 months. “See now I’m gonna must rethink my present and continued boycott of @JAMAcurrent” tweeted Monica McLemore, the editor-in-chief of the journal Well being Fairness, who research reproductive well being and rights in marginalized communities.
Ray Givens, a heart specialist at Emory who analyzed the shortage of racial variety amongst editors at JAMA, known as the choice a good selection. “I anticipated them to decide on a lady of coloration, to protect themselves towards extra criticism,” he informed STAT. “Nevertheless it was additionally the precise factor to do.”
Added Siobhan Wescott, the director of American Indian Well being on the College of Nebraska Medical Middle, “She’s going to be a welcome breath of recent air.”
The seek for a brand new editor was led by Otis Brawley, a Black professor of oncology and epidemiology at Johns Hopkins College whose analysis focuses on closing racial, financial, and social disparities in drugs. The 18-member search committee was extremely various and spent months in its seek for a brand new chief. JAMA is among the world’s most prestigious and extensively circulated medical journals. The journals are editorially impartial from the American Medical Affiliation.
“Dr. Bibbins-Domingo is a first-rate physician-scientist with broad and deep credentials spanning biochemistry, scientific science, inhabitants science and educational analysis,” Brawley mentioned in a press release. Along with her work at UCSF, Bibbins-Domingo served as a member, vice chair, and chair of the U.S. Preventive Companies Job Pressure. Brawley mentioned her work guiding such complicated enterprises “uniquely qualifies her to be JAMA’s subsequent editor-in-chief.”
Bibbins-Domingo began her profession as a biochemist and educated within the lab of Nobelist Harold Varmus.
